WO2005097174A3 - Utilisations de combinaisons de secretagogue gh et d'une hormone de croissance - Google Patents
Utilisations de combinaisons de secretagogue gh et d'une hormone de croissance Download PDFInfo
- Publication number
- WO2005097174A3 WO2005097174A3 PCT/DK2005/000242 DK2005000242W WO2005097174A3 WO 2005097174 A3 WO2005097174 A3 WO 2005097174A3 DK 2005000242 W DK2005000242 W DK 2005000242W WO 2005097174 A3 WO2005097174 A3 WO 2005097174A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghrelin
- combination
- cachexia
- individual
- somatotropin
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 5
- 108010051696 Growth Hormone Proteins 0.000 title abstract 5
- 206010006895 Cachexia Diseases 0.000 title abstract 3
- 102000012004 Ghrelin Human genes 0.000 title 1
- 101800001586 Ghrelin Proteins 0.000 title 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000122 growth hormone Substances 0.000 abstract 3
- 230000000580 secretagogue effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200400575 | 2004-04-07 | ||
DKPA200400575 | 2004-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005097174A2 WO2005097174A2 (fr) | 2005-10-20 |
WO2005097174A3 true WO2005097174A3 (fr) | 2005-12-29 |
Family
ID=34981400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2005/000242 WO2005097174A2 (fr) | 2004-04-07 | 2005-04-07 | Utilisations de combinaisons de secretagogue gh et d'une hormone de croissance |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005097174A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045314A2 (fr) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique |
AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
WO2010054446A1 (fr) * | 2008-11-11 | 2010-05-20 | Ademovic Zlatko | Combinaison de deux peptides ou plus dans un composé pharmaceutique unique lyophilisé et stable |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997024369A1 (fr) * | 1995-12-28 | 1997-07-10 | Pfizer Inc. | Composes secretagogues d'hormone de croissance |
WO2000012047A2 (fr) * | 1998-09-02 | 2000-03-09 | Merck & Co., Inc. | Stimulation du retour a des conditions de vie independantes au moyen d'un secretagogue d'hormone de croissance |
WO2000026252A1 (fr) * | 1998-11-03 | 2000-05-11 | Novo Nordisk A/S | Composes presentant des proprietes de liberation d'hormone de croissance |
WO2000048623A1 (fr) * | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Nouveaux derives amide secretagogues de l'hormone de croissance |
US20030139348A1 (en) * | 1994-11-16 | 2003-07-24 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
WO2004032952A1 (fr) * | 2002-10-10 | 2004-04-22 | Gastrotech Pharma A/S | Utilisation de la ghreline dans le traitement de la malnutrition chez des individus gastrectomises |
WO2005014032A2 (fr) * | 2003-08-06 | 2005-02-17 | Gastrotech Pharma A/S | Utilisations de secretagogues |
-
2005
- 2005-04-07 WO PCT/DK2005/000242 patent/WO2005097174A2/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139348A1 (en) * | 1994-11-16 | 2003-07-24 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
WO1997024369A1 (fr) * | 1995-12-28 | 1997-07-10 | Pfizer Inc. | Composes secretagogues d'hormone de croissance |
WO2000012047A2 (fr) * | 1998-09-02 | 2000-03-09 | Merck & Co., Inc. | Stimulation du retour a des conditions de vie independantes au moyen d'un secretagogue d'hormone de croissance |
WO2000026252A1 (fr) * | 1998-11-03 | 2000-05-11 | Novo Nordisk A/S | Composes presentant des proprietes de liberation d'hormone de croissance |
WO2000048623A1 (fr) * | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Nouveaux derives amide secretagogues de l'hormone de croissance |
WO2004032952A1 (fr) * | 2002-10-10 | 2004-04-22 | Gastrotech Pharma A/S | Utilisation de la ghreline dans le traitement de la malnutrition chez des individus gastrectomises |
WO2005014032A2 (fr) * | 2003-08-06 | 2005-02-17 | Gastrotech Pharma A/S | Utilisations de secretagogues |
Non-Patent Citations (3)
Title |
---|
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2004 (2004-02-01), KOUTKIA, P. ET AL.: "Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy", XP002353699, Database accession no. NLM14559725 * |
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2002 (2002-06-01), SHUTO, Y. ET AL.: "Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity", XP002353700, Database accession no. NLM12045256 * |
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2002 (2002-09-01), YAKAR, S. ET AL.: "Circulating levels of IGF-1 directly regulate bone growth and density", XP002353701, Database accession no. NLM12235108 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005097174A2 (fr) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3434687A3 (fr) | Dérivés inédits d'oxyntomoduline et composition pharmaceutique destinée au traitement de l'obésité en contenant | |
WO2006058539A3 (fr) | Ligands du recepteur 1a de secretagogue de l'hormone de croissance | |
WO2006050002A3 (fr) | Compositions destinees a l'administration controlee de composes pharmaceutiquement actifs | |
WO2007038506A3 (fr) | Methode de traitement de la cachexie | |
WO2009129437A3 (fr) | Procédé et compositions pour le traitement de la douleur postopératoire incluant de la clonidine | |
WO2006032042A3 (fr) | Procedes pour traiter l'obesite au moyen d'agents therapeutiques | |
EP2371853A3 (fr) | Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement | |
WO2004071529A3 (fr) | Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i | |
MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
WO2006029036A3 (fr) | Therapie combinee avec du glatiramere acetate et de la n-acetylcysteine pour traiter la sclerose en plaques | |
WO2006045319A3 (fr) | Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique | |
ZA200703166B (en) | Composition comprising lactic acid and lactoferrin | |
WO2006045314A3 (fr) | Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique | |
WO2007014253A3 (fr) | Methode permettant de traiter ou de prevenir la deterioration, les lesions ou les dommages tissulaires causes par l'insuffisance cardiaque congestive | |
WO2009019708A3 (fr) | Compositions pharmaceutiques et procédés pour le traitement du cancer | |
WO2005097174A3 (fr) | Utilisations de combinaisons de secretagogue gh et d'une hormone de croissance | |
WO2005014032A3 (fr) | Utilisations de secretagogues | |
IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
WO2006045313A3 (fr) | Utilisations de secretagogues pour le traitement de patients ayant subi une greffe d'organe | |
WO2009070564A3 (fr) | Compositions et procédés utilisables dans le cadre de la prévention d'infections associées à des implants transcutanés ostéointégrés | |
WO2008099804A1 (fr) | Agent thérapeutique pour la cataracte diabétique | |
PL1699468T3 (pl) | Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego | |
WO2005056520A8 (fr) | Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie | |
WO2006096079A3 (fr) | Composition pharmaceutique comprenant un analogue biosynthetique d'insuline humaine et son utilisation pour traiter le diabete sucre. | |
JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |